By using www.3bfuturehealth.com website you agree to our use of cookies to enhance your experience.
We have updated our Terms of Use, Privacy & Cookies Policies in October 2022. To review them please follow the links below
Terms of Use | Privacy and Cookies Policy
19 October 2022
Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors
28 June 2022
Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology
10 May 2022
Domain Therapeutics raises $42m Series A financing
Thank you for your form submission, we will get in contact with you shortly.